effect of omega-3 on Hidradenitis Supprativa

The effects of omega-3 supplementation on Athrogenic Index of Plasma, Lipid Profile, Glycemic Indices and Liver Enzymes in patients with Hidradenitis Suppurativa

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230123057193N7

Enrollment

Registered

2026-01-01

Start date

2026-01-05

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis suppurativa. Hidradenitis suppurativa

Interventions

Intervention 1: Intervention group: Individuals in this group will receive two capsules containing 1000 mg of omega-3 (containing 120 mg of DHA and 180 mg of EPA) daily for 8 weeks. Omega-3 capsules w

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Ages between 20 to 50 years Diagnosis of hidradenitis suppurativa based on clinical examinations performed by a dermatologist and the Hurley criteria and IHS4 Score BMI above 25 Severity of the disease according to Hurley criteria Stage 1 and 2

Exclusion criteria

Exclusion criteria: Any history of alcohol and tobacco use Breastfeeding and pregnancy or intention to become pregnant within the next 3 months Use of corticosteroids, methotrexate and anticoagulants Diabetes and any diagnosed neoplasia or malignancy Use of antioxidants and omega-3 supplements within the past 3 months

Design outcomes

Primary

Measure	Time frame
Lipid Profile. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Plasma atherogenic index. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;LDL to HDL ratio. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;Ratio of Non-HDL Cholesterol to HDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;Liver enzyme levels. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Insulin. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: ELISA.;Glucose. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Pain Severity. Timepoint: ?????? ?????? (??? ?? ???? ??????) ? 8 ???? ?? ?? ??????. Method of measurement: Visual Analogue Scale.;Dermatological Disease Quality of Life Index (DLQI). Timepoint: ?????? ?????? (??? ?? ???? ??????) ? 8 ???? ?? ?? ??????. Method of measurement: Dermatology Life Quality Index.	—

Measure

Time frame

Lipid Profile. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Plasma atherogenic index. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;LDL to HDL ratio. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;Ratio of Non-HDL Cholesterol to HDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Using the formula.;Liver enzyme levels. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Insulin. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: ELISA.;Glucose. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after the intervention. Method of measurement: Measured using an automated analyzer.;Pain Severity. Timepoint: ?????? ?????? (??? ?? ???? ??????) ? 8 ???? ?? ?? ??????. Method of measurement: Visual Analogue Scale.;Dermatological Disease Quality of Life Index (DLQI). Timepoint: ?????? ?????? (??? ?? ???? ??????) ? 8 ???? ?? ?? ??????. Method of measurement: Dermatology Life Quality Index.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoraiya Ebrahimpor Koujan

Tehran University of Medical Sciences

nutri.seam1@gamil.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026